June 8, 2020 11:01 AM EDT

Insmed's anti-inflammatory drug wins breakthrough status; Kyowa Kirin backs new fund from 4BIO Capital

Natalie Grover

Reporter

John Carroll

Editor & Founder

→ A mixed mid-stage readout of Insmed‘s anti-inflammatory drug, INS1007, read more like a win given the low expectations for the trial back in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Insmed's anti-inflammatory drug wins breakthrough status; Kyowa Kirin backs new fund from 4BIO Capital

Natalie Grover

Reporter

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Ozempic makes list for next round of Medicare drug price negotiations

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

Roche's cardiometabolic chief warns against weight loss 'obsession' with GLP-1s

In­s­med's an­ti-in­flam­ma­to­ry drug wins break­through sta­tus; Ky­owa Kirin backs new fund from 4BIO Cap­i­tal

Reporter

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Insmed's anti-inflammatory drug wins breakthrough status; Kyowa Kirin backs new fund from 4BIO Capital